Pharmaceutical giant Eli Lilly has partnered with AbCellera Biologics, a biotechnology company based in Canada, to address the new coronavirus crisis by developing antibody products to treat and prevent the virus, The Wall Street Journal reported.
AbCellera uses machine learning to find antibody therapies and received a blood sample in February from a patient diagnosed with COVID-19. By screening more than 5 million immune cells and using machine learning to identify which can produce antibodies to neutralize COVID-19, AbCellera identified more than 500 promising antibodies in less than one week.
AbCellera is just one of many companies in the space leveraging AI and machine learning to deal with the pandemic and find desperately-needed solutions.
See the full story below: